Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.357
Sell
RSI(14)
39.367
Neutral
STOCH(KDJ)(9,3,3)
29.625
Neutral
ATR(14)
0.837
Low Volatility
CCI(14)
-130.422
Sell
Williams %R
76.616
Sell
TRIX(12,20)
-0.154
Sell
StochRSI(14)
25.079
Sell
Sanofi SA
SNY47.820USD
-0.860-1.77%
Close 12/15, 16:00（ET）Quotes delayed by 15 min
116.40BMarket Cap
11.57P/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Sanofi SA
Currency: USD Updated: 2025-12-12Key Insights
Sanofi SA's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 69/159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 61.88.In the medium term, the stock price is expected to remain stable.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Sanofi SA's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
9
analysts
Buy
Current Rating
61.882
Target Price
+27.75%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Sanofi SA Highlights
StrengthsRisks
Sanofi SA is a France-based healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.
High Dividend
The company is a high dividend payer, with the latest dividend payout ratio of 171.67%.
Stable Dividend
The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 171.67%.
Undervalued
The company’s latest PE is 11.78, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 251.34M shares, decreasing 9.80% quarter-over-quarter.
Held by Richard Pzena
Star Investor Richard Pzena holds 6.67K shares of this stock.
Financial Health
Currency: USD Updated: 2025-12-12The current financial score of Sanofi SA is 8.60, ranking 52/159 in the Pharmaceuticals industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 15.39B, representing a year-over-year decrease of 1.03%, while its net profit experienced a year-over-year decrease of 5.89%.
Score
Financials
6.72
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
8.63
Operational Efficiency
10.00
Growth Potential
10.00
Shareholder Returns
7.65
Sanofi SA's Company Valuation
Currency: USD Updated: 2025-12-12The current valuation score of Sanofi SA is 5.82, ranking 141/159 in the Pharmaceuticals industry. Its current P/E ratio is 11.78, which is 172.64% below the recent high of 32.11 and 5.12% above the recent low of 11.18.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 69/159
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2025-12-12The current earnings forecast score of Sanofi SA is 8.22, ranking 48/159 in the Pharmaceuticals industry. The average price target for Sanofi SA is 58.58, with a high of 74.67 and a low of 56.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
9
analysts
Buy
Current Rating
61.882
Target Price
+27.75%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
171
Total
6
Median
8
Average
Company name
Ratings
Analysts
Sanofi SA
SNY
9
Biogen Inc
BIIB
36
Amgen Inc
AMGN
35
Vertex Pharmaceuticals Inc
VRTX
33
Eli Lilly and Co
LLY
33
AbbVie Inc
ABBV
32
1
2
3
...
34
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2025-12-12The current price momentum score of Sanofi SA is 6.71, ranking 111/159 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 51.63 and the support level at 46.76, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
48.290
Sell
MA10
48.786
Sell
MA20
49.383
Sell
MA50
49.823
Sell
MA100
49.016
Sell
MA200
50.526
Sell
Institutional Confidence
Currency: USD Updated: 2025-12-12The current institutional shareholding score of Sanofi SA is 3.00, ranking 92/159 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 10.32%, representing a quarter-over-quarter decrease of 4.91%. The largest institutional shareholder is Van Duyn Dodge & E. Morris Cox, holding a total of 68.93M shares, representing 2.83% of shares outstanding, with 2.26% decrease in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
Managed Account Advisors LLC
Invesco Advisers, Inc.
Wellington Management Company, LLP
Putnam Investment Management, L.L.C.
Boston Partners
Mondrian Investment Partners Ltd.
1
2
Risk Assessment
Currency: USD Updated: 2025-12-12The current risk assessment score of Sanofi SA is 8.63, ranking 27/159 in the Pharmaceuticals industry. The company's beta value is 0.44. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.
Score
Beta vs S&P 500 index
0.44
VaR
+2.15%
240-Day Maximum Drawdown
+24.15%
240-Day Volatility
+27.67%
Return
Best Daily Return
60 days
+5.42%
120 days
+5.42%
5 years
+8.06%
Worst Daily Return
60 days
-2.87%
120 days
-9.14%
5 years
-19.13%
Sharpe Ratio
60 days
+0.17
120 days
+0.05
5 years
+0.32
Risk Assessment
Maximum Drawdown
240 days
+24.15%
3 years
+24.57%
5 years
+34.88%
Return-to-Drawdown Ratio
240 days
-0.04
3 years
-0.03
5 years
+0.02
Skewness
240 days
-0.82
3 years
-2.39
5 years
-1.66
Volatility
Realised Volatility
240 days
+27.67%
5 years
+25.50%
Standardised True Range
240 days
+2.13%
5 years
+1.85%
Downside Risk-Adjusted Return
120 days
+6.39%
240 days
+6.39%
Maximum Daily Upside Volatility
60 days
+23.07%
Maximum Daily Downside Volatility
60 days
+20.90%
Liquidity
Average Turnover Rate
60 days
+0.18%
120 days
+0.20%
5 years
--
Turnover Deviation
20 days
+6.70%
60 days
+2.42%
120 days
+15.16%
Peer Comparison
Pharmaceuticals
Sanofi SA
SNY
7.17 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Jazz Pharmaceuticals PLC
JAZZ
8.88 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Prestige Consumer Healthcare Inc
PBH
8.72 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Collegium Pharmaceutical Inc
COLL
8.69 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Catalyst Pharmaceuticals Inc
CPRX
8.63 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
United Therapeutics Corp
UTHR
8.61 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
FAQs
How does TradingKey generate the Stock Score of Sanofi SA?
The TradingKey Stock Score provides a comprehensive assessment of Sanofi SA based on 34 indicators derived from over 100 underlying data points. These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Sanofi SA’s performance and outlook.
How do we generate the financial health score of Sanofi SA?
To generate the financial health score of Sanofi SA, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns. By integrating these comprehensive data, the financial health score not only reflects Sanofi SA's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Sanofi SA.
How do we generate the company valuation score of Sanofi SA?
To generate the company valuation score of Sanofi SA, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Sanofi SA’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value. By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Sanofi SA’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Sanofi SA.
How do we generate the earnings forecast score of Sanofi SA?
To calculate the earnings forecast score of Sanofi SA, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.Comparing these indicators against peers provides context for the stock’s performance and helps
anchor more realistic expectations.These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Sanofi SA’s future.
How do we generate the price momentum score of Sanofi SA?
When generating the price momentum score for Sanofi SA, we examine momentum indicators including support and resistance levels as well as volume metrics.Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.This comprehensive approach can reflect market sentiment and enable rational forecasts of Sanofi SA’s prices. A higher score indicates a more stable short-term price trend for Sanofi SA.
How do we generate the institutional confidence score of Sanofi SA?
To generate the institutional confidence score of Sanofi SA, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Sanofi SA’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Sanofi SA.
How do we generate the risk management score of Sanofi SA?
To assess the risk management score of Sanofi SA, we examine multiple key indicators related to returns, risk, volatility, and liquidity.The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.These indicators together provide a multi-dimensional understanding of Sanofi SA’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Sanofi SA.
